Simplexa" Flu A/B & RSV Direct, Model Number: MOL2650. 510(k) K120413 Simplexa" Flu A/B & RSV Direct. The Focus Diagnostics Simplexa Flu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycler instrument for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use as an aid in the differential diagnosis of influenza A, influenza B, and RSV viral infections in humans and is not intended to detect influenza C.
Publicado el 9 de julio de 2014 · Inicio del retiro: 15 de mayo de 2014
Resumen
FDA registra el retiro Z-1958-2014 de dispositivos médicos de Clase II, publicado el 9 de julio de 2014 e iniciado el 15 de mayo de 2014. Empresa responsable: Focus Diagnostics Inc; Estado: Finalizado; Cantidad reportada: 614 kits; Lote: Model Number: MOL2650. All Lot Numbers. The expiration date of the 614 kits of MOL2650 that are impacted by this Correction ranges from 10/31/2014 to 5/31/2015. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Focus Diagnostics is providing an urgent safety notice for a correction to the labeling for Simplexa" Flu A/B & RSV Direct (MOL2650). Focus Diagnostics received some customer complaints of Simplexa Flu A/B & RSV Direct assays with sporadic false signals, which may result in a higher false results rate due to a potential software spectral matrix and Direct Amplification Disc storage.
Qué hacer
Voluntary: Firm initiated · E-Mail
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Focus Diagnostics Inc
- Distribuidor
- Nationwide Distribution
- Lote
- Model Number: MOL2650. All Lot Numbers. The expiration date of the 614 kits of MOL2650 that are impacted by this Correction ranges from 10/31/2014 to 5/31/2015.
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDALegionella IFA Substrate Slide (IF0951) intended for qualitatively detecting and semi-quantitating human serum5 de abril de 2017
- FDALaceration Kit: W/Needles, Sterile Single Use, Latex Free, 20/case, Medical Action Industries, Inc, Arden, NC.9 de julio de 2014
- FDAAtrium Express Dry Seal Chest Drain ATS Blood Recovery, Catalog Number: 4050-100N. Autotransfusion Apparatus.9 de julio de 2014
- FDASimplexa Flu AlB & RSV Direct Assay Kits, intended for use as an aid in the differential diagnosis of12 de marzo de 2014
- FDASimplexa Flu A/B & RSV Direct assay, Model MOL2650. The Focus Diagnostics Simplexa Flu A/B & RSV Direct assay5 de febrero de 2014
- FDAWest Nile Virus IgG DxSelect" kit Catalog No. EL0300G Kit Lots 122150, 122155, 122641, 122650 and 122859 that7 de noviembre de 2012
Preguntas sobre este retiro
¿Simplexa" Flu A/B & RSV Direct, Model Number: MOL2650. 510(k) K120413 Simplexa" Flu A/B & RSV Direct. The Focus Diagnostics Simplexa Flu A/B & RSV Direct assay is intended for use on the 3M Integrated Cycler instrument for the in vitro qualitative detection and differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use as an aid in the differential diagnosis of influenza A, influenza B, and RSV viral infections in humans and is not intended to detect influenza C. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1958-2014 el 9 de julio de 2014. Peligro reportado: Focus Diagnostics is providing an urgent safety notice for a correction to the labeling for Simplexa" Flu A/B & RSV Direct (MOL2650). Focus Diagnostics received some customer complaints of Simplexa Flu A/B & RSV Direct assays with sporadic false signals, which may result in a higher false results rate due to a potential software spectral matrix and Direct Amplification Disc storage.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · E-Mail